Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03783715 · ClinicalTrials.gov registry record
Characterization of Treatment Responses in Lymphedema
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03783715: Clinical Trial study, sponsored by Stanford University.
NCT03783715 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03783715 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study is designed to investigate the treatment response of lymphedema, of the upper or lower extremity, during clinical, pharmacologic treatment of lymphedema with oral ketoprofen. Correlation of clinical responses (changes in limb volume and skin thickness) with changes in the inflammasome will help to define the molecular substrate of treatment response.
Primary Outcome
The systemic inflammatory response of G-CSF, in patients treated with Ketoprofen will be assessed with Luminex-bead inflammasome analysis at baseline and 6 months post-treatment plasma samples. G-CSF, a glycoprotein, is an inflammatory cytokine produced by endothelium and immune cells. Ketoprofen is a unique NSAID possessing dual pathways of inflammatory inhibition, blocking cyclooxygenase (COX) and arachidonate 5-lipoxygenase (5-LO). Measurement using median fluorescence intensity (MFI) will be
Interventions
- DRUG Ketoprofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-06-21 |
| Est. Completion | 2023-08-31 |
Why NCT03783715 stopped before completion
NCT03783715 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ketoprofen is the first listed.
NCT03783715 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03783715 about?
NCT03783715 is a clinical study titled "Characterization of Treatment Responses in Lymphedema". This study is designed to investigate the treatment response of lymphedema, of the upper or lower extremity, during clinical, pharmacologic treatment of lymphedema with oral ketoprofen. Correlation of clinical responses (changes in limb volume and skin thickness) with changes in the inflammasome wil...
What is the current status of trial NCT03783715?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-06-21. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT03783715?
The interventions under investigation include: Ketoprofen (DRUG).
Who is sponsoring clinical trial NCT03783715?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI